UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)

被引：0
|
作者：
Gullick, G. [1 ]
Owen, C. [2 ]
Cook, S. [3 ]
Helbrow, J. [4 ]
Squires, R. [1 ]
Reed, H. M. [1 ]
Park, S.
Weir, E. [5 ]
Aquilina, F. [5 ]
Webber, N. [6 ]
Nye, E. [6 ]
Atkinson, C. [3 ]
Blair, C. [1 ]
Halstead, A. [1 ]
Daniels, E. [4 ]
Alves, A. [1 ]
Chew, S. [5 ]
Thomas, W. [4 ]
Spensley, S. [3 ]
Robinson, T. [2 ]
机构：
[1] Bristol Canc Inst, Med Oncol Dept, Bristol, England
[2] Univ Bristol, Fac Hlth Sci, Bristol Med Sch, Bristol, England
[3] Taunton & Somerset NHS Fdn Trust, Oncol Dept, Musgrove Pk Hosp, Taunton, England
[4] Gloucestershire Hosp NHS Fdn Trust, Oncol Dept, Gloucestershire Oncol Ctr, Cheltenham Gen Hosp, Cheltenham, England
[5] NHS Royal Devon Univ Healthcare, Oncol Dept, Royal Devon & Exeter Hosp Wonford, Exeter, England
[6] Royal United Hosp Bath NHS Fdn trust, Oncol Dept, Bath, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
422P
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [31] Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis.
    Desnoyers, Alexandra
    Nadler, Michelle
    Kumar, Vikaash
    Saleh, Ramy
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] RETRACTION: Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC) (Retraction of Vol 39, Pg 1053, 2021)
    Raimondi, Lucrezia
    Giaconi, Laura
    Spinelli, Gian Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3999 - 3999
  • [33] CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES
    Harbeck, N.
    Bartlett, M.
    Spurden, D.
    Hooper, B.
    Zhan, L.
    Rosta, E.
    Cameron, C.
    Mitra, D.
    Zhou, A.
    VALUE IN HEALTH, 2020, 23 : S27 - S27
  • [34] Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1148 - +
  • [35] Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).
    Palmero, Lorenza
    Mazzeo, Roberta
    Buriolla, Silvia
    Allegri, Lorenzo
    Bortot, Lucia
    Franzoni, Alessandra
    Michelotti, Anna
    Stefani, Elisabetta Camilla
    Turra, Giulia
    Zilli, Miriam
    Di Nardo, Paola
    Roncato, Rossana
    Bonotto, Marta
    Cecchin, Erika
    Belletti, Barbara
    Toffoli, Giuseppe
    Gerratana, Lorenzo
    Baldassarre, Gustavo
    Damante, Giuseppe
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions
    Pla, H.
    Recalde Penabad, S.
    Vinas Villaro, G.
    Margeli Vila, M.
    Obadia Gil, V. L.
    Cirauqui Cirauqui, B.
    Del Barco Berron, S.
    J. Gil, M.
    Quiroga Garcia, V.
    Teruel-Garcia, I.
    Pernas Simon, S.
    Stradella, A.
    Esteve Gomez, A. M.
    Felip, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S660 - S660
  • [37] Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
    Low, Jia Li
    Lim, Elaine
    Bharwani, Lavina
    Wong, Andrea
    Wong, Karmen
    Ow, Samuel
    Lim, Siew Eng
    Lee, Matilda
    Choo, Joan
    Lim, Joline
    Chan, Gloria
    Walsh, Robert John
    Muthu, Vaishnavi
    Ngoi, Natalie
    Chong, Wanqin
    Tan, Sing Huang
    Lee, Soo Chin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [38] Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data
    Kubeczko, Marcin
    Gabrys, Dorota
    Polakiewicz-Gilowska, Anna
    Bobek-Billewicz, Barbara
    Jarzab, Michal
    PHARMACEUTICALS, 2024, 17 (07)
  • [39] Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis
    Kubeczko, Marcin
    Polakiewicz-Gilowska, Anna
    Swiderska, Katarzyna
    Lesniak, Aleksandra
    Mianowska-Malec, Marta
    Lanoszka, Barbarba
    Chomik, Konstanty
    Grandys, Barbara
    Lisovska, Natalya
    Bobek-Billewicz, Barbara
    Chmielik, Ewa
    Jarzab, Michal
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition
    Guo, Xianan
    Chen, Huihui
    Zhou, Yunxiang
    Shen, Lu
    Wu, Shijie
    Chen, Yiding
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (09) : 933 - 944
12345